Ovarian cancer: screening and early detectionBarbara A Goff
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195 6460, USA
Obstet Gynecol Clin North Am 39:183-94. 2012
..Finally, clinicians must always listen carefully to their patients avoid potentially harmful delays in diagnosis. Until there is a screening test, awareness is best...
- Symptoms associated with ovarian cancer
Barbara Goff
Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA
Clin Obstet Gynecol 55:36-42. 2012
..It is important for women and practitioners to be aware that ovarian cancer is not a "silent disease."..
Symptom triggered screening for ovarian cancer: a pilot study of feasibility and acceptabilityBarbara A Goff
University of Washington, Department of Obstetrics and Gynecology, Seattle, WA 98195 6460, USA
Gynecol Oncol 124:230-5. 2012
..Our goal was to determine if symptom-based ovarian cancer screening was feasible in a primary care clinic and acceptable to women and practitioners. In addition, we wanted to describe the outcomes for a pilot group of screened women...
- Training and assessment in gynaecologic surgery: the role of simulation
Barbara A Goff
Department of Obstetrics and Gynaecology, University of Washington School of Medicine, Seattle, 98195 6460, United States
Best Pract Res Clin Obstet Gynaecol 24:759-66. 2010
..Most importantly, it requires desire on the part of the trainees to devote the hours of practise needed to make themselves accomplished surgeons...
- How are symptoms of ovarian cancer managed? A study of primary care physicians
Barbara A Goff
Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA
Cancer 117:4414-23. 2011
..A study was undertaken to identify the diagnostic approaches that primary care physicians and gynecologists undertake in women with symptoms associated with ovarian cancer...
- Involvement of gynecologic oncologists in the treatment of patients with a suspicious ovarian mass
Barbara A Goff
Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA
Obstet Gynecol 118:854-62. 2011
..To identify the factors associated with inclusion of a gynecologic oncologist in managing the care of a woman with suspected ovarian cancer...
- Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer
M Robyn Andersen
Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Gynecol Oncol 116:378-83. 2010
..Prior studies suggest that combining the Symptom Index (SI) with a serum HE4 test or a CA125 test may improve prediction of ovarian cancer. However, these three tests have not been evaluated in combination...
- Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer
Melissa M Thrall
Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA, USA
Gynecol Oncol 123:461-6. 2011
..While NAC may facilitate and simplify complete cytoreduction and reduce the risk of surgery, the delay of surgery related to NAC needs to be balanced against any potential benefit...
- Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer
Heidi J Gray
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington Medical Center, Seattle, WA 98195, USA
Gynecol Oncol 116:340-4. 2010
..We hypothesized that women treated with alternative IP chemotherapy strategies may have less toxicity and improved compliance...
Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomasVijaya Galic
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle, WA 98195, USA
Genes Chromosomes Cancer 46:239-47. 2007
..04). Somatic mutation or deletion was equally common for either codon 72 allele. Age of diagnosis was not influenced by codon 72 but showed a trend for younger age in women with somatic TP53 mutations and the MDM2 G/G genotype...
- Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study
Kathryn F McGonigle
Women s Cancer Care of Seattle, Seattle, Washington 98133, USA
Cancer 117:3731-40. 2011
..A phase 2 trial was conducted to determine the toxicity and efficacy of combined weekly topotecan and biweekly bevacizumab in patients with primary or secondary platinum-resistant ovarian, peritoneal, or fallopian tube cancer (OC)...
- The temporal stability of the Symptom Index among women at high-risk for ovarian cancer
Kimberly A Lowe
Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Gynecol Oncol 114:225-30. 2009
..To evaluate the temporal stability of self-reported symptoms known to be associated with ovarian cancer...
- The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations
Barbara M Norquist
Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA, USA
Cancer 116:5261-71. 2010
..BRCA1 or BRCA2 (BRCA1/2)-mutated ovarian carcinomas may originate in the fallopian tube. The authors of this report investigated alterations in BRCA1/2 tubal epithelium to define the molecular pathogenesis of these carcinomas...
- Predictors of comprehensive surgical treatment in patients with ovarian cancer
Barbara A Goff
Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington 98195 6460, USA
Cancer 109:2031-42. 2007
..In this study, the authors identified factors that were associated with a measure of comprehensive surgery, so that interventions may be targeted appropriately to improve surgical care...
- Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers
Joshua Z Press
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA
Neoplasia 12:993-1002. 2010
..The expression of a subset of genes was validated with quantitative reverse transcription-polymerase chain reaction and immunohistochemistry...
- Development of an ovarian cancer symptom index: possibilities for earlier detection
Barbara A Goff
Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, Washington 98196 6460, USA
Cancer 109:221-7. 2007
..Currently, screening for ovarian cancer is not recommended for the general population. Targeting women with specific symptoms for screening has been evaluated only recently, because it was believed that symptoms had limited specificity...
- Microparticles from ovarian carcinomas are shed into ascites and promote cell migration
Joshua Z Press
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA, USA
Int J Gynecol Cancer 22:546-52. 2012
....
- Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas
Elizabeth M Swisher
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA
Mol Cancer 8:48. 2009
..Additionally, we assessed whether promoter methylation of BRCA1, MLH1 or FANCF influenced response to chemotherapy or explained alterations in protein expression after chemotherapy exposure...
- Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma
Ruchi Garg
Division of Gynecologic Oncology, University of Washington Medical Center, Seattle 98195, USA
Gynecol Oncol 103:793-6. 2006
..The IL6 -174 promoter polymorphism impacts serum cytokine levels through transcriptional regulation. The objective of our study was to determine if -174 IL6 genotype influences survival in ovarian cancer...
- Vignette-based study of ovarian cancer screening: do U.S. physicians report adhering to evidence-based recommendations?
Laura Mae Baldwin
University of Washington, Seattle, Washington 98195 4982, USA
Ann Intern Med 156:182-94. 2012
..No professional society or group recommends routine ovarian cancer screening, yet physicians' enthusiasm for several cancer screening tests before benefit has been proven suggests that some women may be exposed to potential harms...
- Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly
Melissa M Thrall
Department of Obstetrics, University of Washington School of Medicine, University of Washington, Seattle, Washington 98195 6460, USA
Obstet Gynecol 118:537-47. 2011
..To identify factors associated with increased 30-day mortality after advanced ovarian cancer debulking among elderly women...
- Comparison of objective, structured assessment of technical skills with a virtual reality hysteroscopy trainer and standard latex hysteroscopy model
Barbara A Goff
Department of Obstetrics and Gynecology, Box 356460, University of Washington School of Medicine, Seattle, WA 98195 6460, USA
J Reprod Med 52:407-12. 2007
..To evaluate a virtual reality (VR) hysteroscopy device and a standard latex hysteroscopy model for assessment of residents' surgical skills...
- Combining a symptoms index with CA 125 to improve detection of ovarian cancer
M Robyn Andersen
Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Cancer 113:484-9. 2008
....
- Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium
Barbara A Goff
Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle WA 98195, USA
Gynecol Oncol 110:146-51. 2008
..To determine the nature and degree of toxicity, response rate, quality of life (QOL), and progression-free interval in women with platinum-resistant refractory ovarian or peritoneal cancer receiving weekly topotecan and gemcitabine...
- Factors affecting risk of mortality in women with vaginal cancer
Chirag A Shah
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Washington, Seattle, Washington 98195 6460, USA
Obstet Gynecol 113:1038-45. 2009
..To estimate the current effect of demographics, pathology, and treatment on mortality among women with vaginal cancer...
- Patterns of spread and recurrence of sex cord-stromal tumors of the ovary
Melissa M Thrall
Department of Obstetrics and Gynecology, University of Washington School of Medicine, Box 356460, Seattle, WA 98195 6460, USA
Gynecol Oncol 122:242-5. 2011
..To confirm these findings, we evaluated pathologic findings in women undergoing surgical management of sex cord-stromal tumors in the Seattle metropolitan area...
- A six-year study of surgical teaching and skills evaluation for obstetric/gynecologic residents in porcine and inanimate surgical models
Gretchen M Lentz
Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA
Am J Obstet Gynecol 193:2056-61. 2005
..Resident surgical skills evaluated by OSATS significantly improve over time both individually and as a cohort by resident year...
- FOXP3+ regulatory T-cells are abundant in vulvar Paget's disease and are associated with recurrence
Joshua Z Press
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA
Gynecol Oncol 120:296-9. 2011
..To characterize clinical features of vulvar Paget's disease, and examine the quantity of immunosuppressive regulatory T-cells in vulvar Paget's tissue...
- Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer
Chirag A Shah
University of Washington Medical Center, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Seattle, Washington 98195, USA
Gynecol Oncol 109:215-9. 2008
..Forty percent of women with ovarian cancer have circulating free tumor DNA. We sought to determine if the tumor immune infiltrate varied based on tumor p53 mutation status or presence of circulating tumor DNA...
- Identification of ovarian cancer symptoms in health insurance claims data
Sean M Devlin
Department of Biostatistics, School of Public Health, University of Washington, Seattle, Washington 98195 9455, USA
J Womens Health (Larchmt) 19:381-9. 2010
....
- Alternate molecular genetic pathways in ovarian carcinomas of common histological types
Julia Willner
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle, WA 98195, USA
Hum Pathol 38:607-13. 2007
..Mutations in p53, PIK3CA, PTEN, and CTNNB1 account for most EC tumors; most CC remain unexplained. EC/CC histology is a favorable prognostic factor...
- Ovarian cancer in the elderly: outcomes with neoadjuvant chemotherapy or primary cytoreduction
Kate A McLean
Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, Washington 98195 6460, USA
Gynecol Oncol 118:43-6. 2010
..Recent studies have suggested inferior outcomes for elderly women with ovarian cancer. Our goal was to evaluate neoadjuvant chemotherapy versus primary cytoreduction in elderly women...
- Ovarian cancer: patterns of surgical care across the United States
Barbara A Goff
Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA
Gynecol Oncol 103:383-90. 2006
..To describe the primary surgical procedures and procedures for intraoperative and postoperative complications, and factors associated with these procedures, in women with ovarian cancer...
- An evaluation of cervical cancer in women age sixty and over
Katrina V Fox
Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, Washington 98195, USA
Gynecol Oncol 109:53-8. 2008
..To assess prior cervical cancer screening, stage at time of diagnosis and outcome in women sixty years of age and over with cervical cancer...
- Genomic structure of chromosome 17 deletions in BRCA1-associated ovarian cancers
Karen M Chisholm
Department of Genome Sciences, University of Washington, 1959 NE Pacific St, Seattle, WA 98195, USA
Cancer Genet Cytogenet 183:41-8. 2008
..In those tumors with retention of part of chromosome 17, LOH margins suggest that a high Alu content may have a role in the deletions...
- Changing the paradigm in surgical education
Barbara A Goff
University of Washington School of Medicine, Seattle, Washington, USA
Obstet Gynecol 112:328-32. 2008
..Identifying more effective methods to teach and assess surgical skills will benefit not only our trainees but also the patients for whom we care...
- Trends in treatment of advanced epithelial ovarian cancer in the Medicare population
Melissa M Thrall
Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA, USA
Gynecol Oncol 122:100-6. 2011
..This study evaluated patterns of care, frequency of completion of recommended therapy and factors associated with sequencing of therapy...
- Involvement in decision-making about treatment and ovarian cancer survivor quality of life
M Robyn Andersen
Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Gynecol Oncol 124:465-70. 2012
....
- Self-assessment of resident surgical skills: is it feasible?
Lynn S Mandel
Department of Obstetrics and Gynecology, University of Washington, Seattle, WA 98195 6460, USA
Am J Obstet Gynecol 193:1817-22. 2005
....
- Pelvic exenteration in the age of modern chemoradiation
Kate A McLean
Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA, USA
Gynecol Oncol 121:131-4. 2011
..To examine outcomes after pelvic exenteration in women treated with modern chemoradiation and surgical techniques...
- Weekly gemcitabine and cisplatin in combination with pelvic radiation in the primary therapy of cervical cancer: a phase I trial of the Puget Sound Oncology Consortium
Elizabeth M Swisher
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, 1959 N E Pacific St, Box 356460, Seattle, WA 98195 6460, USA
Gynecol Oncol 101:429-35. 2006
..Define the maximum tolerated dose of weekly gemcitabine given concomitantly with standard weekly cisplatin and pelvic radiotherapy for primary treatment of cervical cancer...
- Angiogenic alterations associated with circulating neoplastic DNA in ovarian carcinoma
Tilley Jenkins Vogel
Department of Obstetrics and Gynecology, University of Washington, Seattle, WA
Transl Oncol 5:247-51. 2012
..Angiogenesis is critical in neoplastic growth and metastasis. We sought to determine whether circulating neoplastic DNA results from alterations in the balance of angiogenesis activators and inhibitors...
- A new curriculum for hysteroscopy training as demonstrated by an objective structured assessment of technical skills (OSATS)
Amy L VanBlaricom
Department of Obstetrics, University of Washington, Madigan Army Medical Center, Seattle, WA, USA
Am J Obstet Gynecol 193:1856-65. 2005
..CONCLUSION: This curriculum is an effective way to impart knowledge and skill in the assembly and use of the operative hysteroscope. The checklist developed for this OSATS has excellent reliability and construct validity...
- Training the next generation of minimally invasive surgeons
Michael F Fialkow
Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, USA
J Minim Invasive Gynecol 16:136-41. 2009
..Although many questions remain about how to optimally apply and evaluate the educational tools being developed, it appears certain that surgical simulation, in some form, is the educational paradigm of the present and future...
- MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B, CDKNIC and overall survival
Kaitlyn Wurz
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195 6460, USA
Genes Chromosomes Cancer 49:577-84. 2010
..01). In contrast, CDKN1B expression was not associated with miR-221 or miR-222 expression. Neither somatic mutations nor methylation of the studied region explained the alterations in miR-221 and miR-222 expression in most carcinomas...
- Nonrecommended breast and colorectal cancer screening for young women: a vignette-based survey
Hajar Kadivar
Department of Family Medicine, University of Washington, Seattle, Washington, USA
Am J Prev Med 43:231-9. 2012
..Little is known about the prevalence of physicians offering nonrecommended breast or colorectal cancer screening for young women...
- Frequency of symptoms of ovarian cancer in women presenting to primary care clinics
Barbara A Goff
Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle 98195, USA
JAMA 291:2705-12. 2004
..Women with ovarian cancer frequently report symptoms prior to diagnosis, but distinguishing these symptoms from those that normally occur in women remains problematic...
- Evaluation of postoperative fever: usefulness and cost-effectiveness of routine workup
Sarah H de la Torre
Department of Obstetrics and Gynecology, University of Washington Medical Center, Seattle, 98195, USA
Am J Obstet Gynecol 188:1642-7. 2003
..Only patients with these characteristics are most likely to benefit from laboratory and/or radiographic workup of fever...
- Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy
Julie D Lamb
Department of Obstetrics and Gynecology, University of Washington, Seattle, WA 98195-6460, USA
Am J Obstet Gynecol 194:1702-9. 2006
..A thorough pathologic and surgical protocol at the time of risk-reducing salpingo-oophorectomy may improve the risk of subsequent primary peritoneal cancer...
- Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer
Elizabeth M Swisher
Division of Medical Genetics, University of Washington, Seattle, WA, USA
Am J Obstet Gynecol 193:662-7. 2005
..Free tumor DNA in body fluids may be an important biomarker. We tested whether tumor-specific mutated p53 DNA can be detected in blood and peritoneal fluid from women with epithelial ovarian cancer...
- Surgical skills assessment: a blinded examination of obstetrics and gynecology residents
Barbara A Goff
Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, 98195-6460, USA
Am J Obstet Gynecol 186:613-7. 2002
..This study provides further evidence that OSATS can be used to establish surgical competence...
- The abandoned radical hysterectomy for cervical cancer: clinical predictors and outcomes
Heidi J Gray
Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA
Obstet Gynecol Int 2010:743794. 2010
..168). Overall survival in the abandoned group was 73% versus 80% in the completed group (P = .772). Conclusion. The practice of abandoning a planned radical hysterectomy for unexpected metastatic disease may not worsen the outcome...
- The significance of psammoma bodies in screening cervical cytologic smears
Howard G Muntz
Gynecology and Gynecologic Oncology Section, Department of Surgery, Virginia Mason Medical Center, Seattle, WA 98111 0900, USA
Am J Obstet Gynecol 188:1609-12; discussion 1612-4. 2003
....
- Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602)
Barbara A Goff
Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, 98195-6460, USA
Am J Obstet Gynecol 188:1556-62; discussion 1562-4. 2003
..Overall, approximately 55% of women with platinum-resistant ovarian or peritoneal cancer benefit from this regimen with response or stabilization of disease...
